scholarly journals Qingyihuaji Formula Inhibits Progress of Liver Metastases From Advanced Pancreatic Cancer Xenograft by Targeting to Decrease Expression of Cyr61 and VEGF

2011 ◽  
Vol 11 (1) ◽  
pp. 37-47 ◽  
Author(s):  
Jian-Hua Yin ◽  
Wei-Dong Shi ◽  
Xiao-Yan Zhu ◽  
Zhen Chen ◽  
Lu-Ming Liu
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastases ◽  
Advanced Pancreatic Cancer

Development and validation of a radiomics nomogram to discriminate advanced pancreatic cancer patients with liver metastases or other metastatic patterns.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 435-435
Author(s):  
Junjie Hang ◽  
Lixia Wu
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Validation Cohort ◽  
Advanced Pancreatic Cancer ◽  
Region Of Interest ◽  
Calibration Plot ◽  
Training Cohort ◽  
Kaplan Meier ◽  
Metastatic Patterns

435 Background: Pancreatic cancer patients with liver metastases had much poorer prognosis than those with other metastatic patterns. This study aimed to develop and validate a radiomics model to discriminate pancreatic cancer patients with liver metastases from patients with other metastatic patterns. Methods: We evaluated 77 patients advanced pancreatic cancer (APC) with different metastatic patterns and performed texture analysis on the region of interest (ROI). 58 patients and 19 patients were allocated randomly into the training cohort and the validation cohort with almost the same proportion of patients with liver metastases. An independent samples t-test was used for initial feature selection in the training cohort. Random Forest Classifier (RFC) was used to construct models based on these features in both cohorts and a radiomics signature (RS) was derived from the model. Then a nomogram was constructed based on RS and CA19-9, and validated with calibration plot and decision curve. The prognostic value of RS was evaluated by Kaplan-Meier methods. Results: A nomogram based on the RS and CA19-9 was constructed and it demonstrated good discrimination in the training cohort (AUC = 0.93) and validation cohort (AUC = 0.81). Kaplan-meier methods showed that patients with RS>0.61 had much poorer OS than patients with RS < 0.61 in both cohorts. Conclusions:This study presents a radiomics nomogram incorporating both RS and CA19-9, which can be used to discriminate advanced pancreatic cancer patients with liver metastases from patients with other metastatic patterns.

scholarly journals A case of long survival in advanced pancreatic cancer with multiple liver metastases successfully treated by combined chemotherapy of S-1 and gemcitabine

Suizo ◽  
2008 ◽  
Vol 23 (4) ◽  
pp. 510-518
Author(s):  
Shun-ichi ISHIGAMI ◽  
Nobuo BABA ◽  
Kazuhiko KITAGUCHI ◽  
Morito SAKIKUBO ◽  
Ryou KAMIMURA ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastases ◽  
Advanced Pancreatic Cancer ◽  
Combined Chemotherapy ◽  
Long Survival ◽  
Multiple Liver Metastases

scholarly journals Intra-arterial chemotherapy for advanced pancreatic cancer

2019 ◽  
Vol 24 (3) ◽  
pp. 73-86
Author(s):  
A. V. Kozlov ◽  
D. A. Granov ◽  
P. G. Tarazov ◽  
A. V. Pavlovskiy ◽  
L. I. Korytova ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Life Expectancy ◽  
Partial Response ◽  
Liver Metastases ◽  
Metastatic Cancer ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Stage Iv ◽  
Arterial Embolization ◽  
Unresectable Pancreatic Cancer

Objective. To study effectiveness of intra-arterial chemotherapy in patients with locally advanced and metastatic pancreatic cancer.Material and methods. There were 329 patients who underwent regional chemotherapy in 2000 – 2015 (infusion through celiac trunk – 167, chemoembolization of gastroduodenal artery – 52, combination of these methods – 72, combined chemo-radiotherapy – 38). Locally advanced unresectable pancreatic cancer with arterial invasion (T4 grade) was observed in 198 (60.2%) patients, liver metastases (stage IV) – in 131 (39.8%) patients. Chemoembolization or chemoradiation therapy was performed for patients without distant metastases.Results. The best results for unresectable pancreatic cancer were obtained in 160 patients after chemoembolization combined with infusion. Partial response was obtained in 24.1% of cases compared with 8.9% and 13.4% of cases after infusion or chemoembolization alone. Mean life expectancy was 15.5 months compared with 14.6 and 10.6 months, respectively. Median of life expectancy was 15.6 months compared with 11.7 and 10.8 months, respectively. At the same time, progression of disease was observed in the majority of 131 patients with metastatic cancer. Partial response was noted only in 2.3% of patients only after chemoinfusion. Survival and median survival after chemoinfusion and combination of chemoembolization with chemoinfusion were similar (10.1 (8.3) and 10.9 (7.5) months). Chemoradiotherapy in 4 patients with initially unresectable pancreatic cancer resulted reduction of tumor dimension by 28% (24–32%). Therefore, radical operations were performed later. One-year survival was achieved in 20 (58.8%) out of 34 patients with unresectable pancreatic cancer. Mean life expectancy was 15.4 months (median 13.8 months).Conclusion. Intra-arterial chemotherapy is effective treatment in patients with pancreatic cancer stage III and IV. Combination of celiac axis infusion with arterial embolization, as well as infusion with radiotherapy resulted the best survival. Certain advantage of chemoinfusion was found for liver metastases. The use of new chemotherapy modes for intra-arterial infusion requires further study.

Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase II, prospective clinical study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS4169-TPS4169
Author(s):  
Zhiwei Li ◽  
Qingwei Li ◽  
Zhigang Ma ◽  
Yue Ma ◽  
Dan Su ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastases ◽  
Phase Ii ◽  
Objective Response ◽  
Advanced Pancreatic Cancer ◽  
Prospective Clinical Study ◽  
Metastatic Tumors ◽  
Standard Regimen ◽  
Free Survival ◽  
Local Ablation

TPS4169 Background: Pancreatic cancer represents one of the most aggressive tumors and the majority of patients receive a diagnosis of metastatic disease, mainly in the liver, leading to poor prognosis and survival. Currently, chemotherapy has been the treatment of choice for fit patients with pancreatic cancer liver metastases (PCLM), reaching a median survival of about 5 to 7 months. In addition, local ablation of the metastatic tumors, by increasing neoantigen exposure and transforming the immune microenvironment to reduce the progression of liver metastases, might increase the survival benefit of patients. Camrelizumab, an anti-PD-1 monoclonal antibody, has obtained preliminary results in metastatic pancreatic cancer. Therefore, this study aims to explore the effectiveness and safety of camrelizumab combined with ablation and chemotherapy in the treatment of PCLM. Methods: In this single-arm, prospective, phase II study, 34 patients with histological or cytological diagnosis of PCLM, ECOG performance score of 0-1, no prior chemotherapy or the interval of adjuvant chemotherapy ≥6 months, plan to be enrolled. The enrolled patients first received ablation surgery of liver metastases, then chemotherapy (the standard regimen for advanced pancreatic cancer, determined by the investigator) combined with camrelizumab (200 mg, iv, q3w) is administered 1 week after ablation. If the patient has multiple metastatic tumors, the ablation needs to be performed in stages. The treatment regimens will continue until the disease progression, unacceptable toxicity or withdrawal of consent. The primary endpoint is 6-month progress-free survival (6-month PFS) rate (per RECIST v1.1 by researcher). Secondary endpoints are objective response rate, disease control rate, progression-free survival, overall survival and safety. On the basis of a threshold 6-month PFS rate of 25%, targeting an expected 6-month PFS rate of 44% and assuming 18 months follow-up, 80% power and a one-sided α = 0.05, this design requires 34 evaluable patients to be accrued over 2 years. Clinical trial information: NCT04420130.

Development and validation of a radiomics nomogram to discriminate advanced pancreatic cancer with liver metastases or other metastatic patterns

2021 ◽  
pp. 1-10
Author(s):  
Tianliang Zhang ◽  
Xiao Dong ◽  
Yang Zhou ◽  
Muhan Liu ◽  
Junjie Hang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastases ◽  
Advanced Pancreatic Cancer ◽  
Region Of Interest ◽  
Random Forest Classifier ◽  
Calibration Plot ◽  
Good Discrimination ◽  
Kaplan Meier ◽  
Metastatic Patterns ◽  
Development And Validation

BACKGROUND: Patients with advanced pancreatic cancer (APC) and liver metastases have much poorer prognoses than patients with other metastatic patterns. OBJECTIVE: This study aimed to develop and validate a radiomics model to discriminate patients with pancreatic cancer and liver metastases from those with other metastatic patterns. METHODS: We evaluated 77 patients who had APC and performed texture analysis on the region of interest. 58 patients and 19 patients were allocated randomly into the training and validation cohorts with almost the same proportion of liver metastases. An independentsamples t-test was used for feature selection in the training cohort. Random forest classifier was used to construct models based on these features and a radiomics signature (RS) was derived. A nomogram was constructed based on RS and CA19-9, and was validated with calibration plot and decision curve. The prognostic value of RS was evaluated by Kaplan-Meier methods. RESULTS: The constructed nomogram demonstrated good discrimination in the training (AUC = 0.93) and validation (AUC = 0.81) cohorts. In both cohorts, patients with RS > 0.61 had much poorer overall survival than patients with RS < 0.61. CONCLUSIONS: This study presents a radiomics nomogram incorporating RS and CA19-9 to discriminate patients who have APC with liver metastases from patients with other metastatic patterns.

Sign in / Sign up

Export Citation Format

Share Document